Fighting Cancer with Ruthenium Complexes

  • ChemPubSoc Europe Logo
  • Author: Joseph D. Unsay
  • Published Date: 02 August 2017
  • Source / Publisher: Chemistry – A European Journal/Wiley-VCH
  • Copyright: Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim
thumbnail image: Fighting Cancer with Ruthenium Complexes

Related Societies

Photodynamic therapy (PDT) has become a viable treatment against certain types of cancers. PDT uses molecules, e.g., metal complexes, that can generate reactive oxygen species within cancer tissues upon light-activation. The advantage of using metal complexes is the tunability of the ligands, which allows for the possibility of two-photon excitation (resulting in a  lower energy of excitation and deeper tissue penetration). In addition, biologically active ligands can be used (e.g., as DNA intercalators).


Hui Chao, Sun Yat-Sen University, Guangzhou, China, Gilles Gasser, Chimie Paris Tech, PSL Research University, France, and colleagues have synthesized two [Ru(phen)2(dppz)]2+ complexes (phen = phenanthroline; dppz = dipyrido[3,2-a:2',3'-c]-phenazine), differing only in the functional groups of the dppz ligand (Complex 1 has dppz-7,8-(OMe)2, and 2 has dppz-7,8-(OH)2, see scheme).


After characterizing the complexes using crystallographic and spectroscopic techniques, the team evaluated the toxicity of these complexes on a monolayer of HeLa cells. They showed that complex 1, while having some dark toxicity, had an IC50 = 3.1 μM upon one-photon activation (IC50 is a measure for the effectiveness of inhibition of a biological process). With this value, the complex outperforms the known chemotherapeutic drug cisplatin (IC50 = 29.5 μM) and the clinically approved PDT drug ALA (IC50 = 154.8 μM). Complex 1 also showed activity against 3D HeLa spheroids (representing solid tumors) when activated using two-photon excitation (IC50 = 9.5 μM, compared with IC50 = 32.5 μM with one-photon activation, 69.5 μM for cisplatin, and >200 μM for ALA).


 

Article Views: 1324

Sign in Area

Please sign in below

Additional Sign In options

Please note that to comment on an article you must be registered and logged in.
Registration is for free, you may already be registered to receive, e.g., the newsletter. When you register on this website, please ensure you view our terms and conditions. All comments are subject to moderation.

Article Comments - To add a comment please sign in

Bookmark and Share

If you would like to reuse any content, in print or online, from ChemistryViews.org, please contact us first for permission. more


CONNECT:

ChemistryViews.org on Facebook

ChemistryViews.org on Twitter ChemistryViews.org on YouTube ChemistryViews.org on LinkedIn Sign up for our free newsletter


A product of ChemPubSoc Europe (16 European Chemical Societies)and Wiley-VCH